Track Branded Generic Launches with Drug Patent Data: The Competitive Intelligence Playbook
Every year, billions of dollars in branded drug revenue evaporate on a single day: the day a generic or branded […]
Every year, billions of dollars in branded drug revenue evaporate on a single day: the day a generic or branded […]
AbbVie held Humira’s U.S. market alone for twenty years. Not because it held one brilliant patent, but because it built
Pharmaceutical executives who pitch branded generics to their boards often face the same question: why pour marketing dollars into a
Branded Generic ROI: The Cold Math Behind a Controversial Strategy Read Post »
The difference between first place and second place in the generic drug market is not measured in prestige. It is
Launch First or Lose: How Generic Drug Timing Decides Long-Term Profit Read Post »
AbbVie collected roughly $114 billion in U.S. Humira revenue before the first biosimilar cleared a path to pharmacy shelves. Allergan
Every brand team runs the same model. The compound patent expires on a known date. You build a 24-month revenue
The expiration date on a blockbuster drug’s primary patent is almost never the date generic competition arrives. Between that printed
Every few years, a mid-size generic manufacturer files a Paragraph IV certification against a blockbuster drug, gets sued by a
Data Beats Capital: Why the Real Challenger in Pharma IP Is the One Who Knows More Read Post »
Pharmaceutical patent litigation produces more text per dollar at stake than almost any other legal domain. A single Hatch-Waxman case
Sentiment Analysis in Patent Litigation: How to Predict Pharmaceutical Case Outcomes Read Post »
Get fresh news and insights, drug patent expirations & more…